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Abstract
Many individuals with cardiac diseases undergo periodic physical conditioning with or without medication. Therefore, this study
investigated the interaction of physical training and chronic nitric oxide synthase (NOS) inhibitor (nitro-L-arginine methyl ester, L-NAME)
treatment on blood pressure (BP), heart rate (HR) and cardiac oxidant/antioxidant systems in rats. Fisher 344 rats were divided into four
groups and treated as follows: (1) sedentary control (SC), (2) exercise training (ET) for 8 weeks, (3) L-NAME (10 mg/kg, s.c. for 8 weeks)
and (4) ET + L-NAME. BP and HR were monitored with tail-cuff method. The animals were sacrificed 24 h after last treatments and hearts
were isolated and analyzed. Physical conditioning significantly increased respiratory exchange ratio (RER), cardiac nitric oxide (NO) levels,
NOS activity and endothelial (eNOS) and inducible (iNOS) protein expression. Training significantly enhanced cardiac glutathione (GSH)
levels, GSH/GSSG ratio and up-regulation of cardiac copper/zinc-superoxide dismutase (CuZn-SOD), manganese (Mn)-SOD, catalase
(CAT), glutathione peroxidase (GSH-Px) activity and protein expression. Training also caused depletion of cardiac malondialdehyde (MDA)
and protein carbonyls. Chronic L-NAME administration resulted in depletion of cardiac NO level, NOS activity, eNOS, nNOS and iNOS
protein expression, GSH/GSSG ratio and down-regulation of cardiac CuZn-SOD, Mn-SOD, CAT, GSH-PX, glutathione-S-transferase (GST)
activity and protein expression. Chronic L-NAME administration enhanced cardiac xanthine oxidase (XO) activity, MDA levels and protein
carbonyls. These biochemical changes were accompanied by increases in BP and HR after L-NAME administration. Interaction of training
and NOS inhibitor treatment resulted in normalization of BP, HR and up-regulation of cardiac antioxidant defense system. The data suggest
that physical conditioning attenuated the oxidative injury caused by chronic NOS inhibition by up-regulating the cardiac antioxidant defense
system and lowering the BP and HR in rats. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Population throughout the world performs regular phys-
ical activity to maintain good cardiovascular health. Many
individuals with cardiovascular diseases participate in
organized group exercise rehabilitation programs or pursue
individual physical activity with or without medication.
Reactive oxygen species (ROS) and free radicals are medi-
ators of several forms of tissue damage, such as ischemic
injuries to different organs, inflammatory response, and
injury resulting from intracellular metabolism of drugs and
chemicals [6,40]. There has been recent interest in the con-
cept that oxygen free radicals and nitric oxide (NO
S
) play an
important role in the pathogenesis of cardiovascular diseases
[6]. However, the cardiovascular system has a series of
defense mechanism including antioxidant enzymes—super-
oxide dismutase (SOD), catalase (CAT), glutathione perox-
idase (GSH-Px), glutathione disulfide reductase (GR)—and
other free radical scavengers, beta-carotene, alpha-toco-
pherol, ascorbic acid, alpha-lipoic acid and glutathione
(GSH) to protect the cell against cytotoxic ROS, such as
superoxide anion (O2
S 
), hydrogen peroxide (H2O2) and
hydroxyl radical (HO
S
). Exercise increases the utilization of
oxygen in the body, and seems to enhance the free radical
formation in various tissues of the body [7,40]. Exercise
generated free radicals seem to increase the activity of anti-
oxidant enzymes in the heart [33,41]. Acute physical stress
causes depletion of NO levels whereas training increases
NO levels in the cardiovascular system by induction of nitric
oxide synthase (NOS) [38,49]. The benefit of regular
physical activity has been reported to improve cardiovas-
cular functions in patients with chronic heart failure and
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other cardiovascular diseases [16,30]. However, the exact
mechanism in the regulation of cardiovascular functions
[blood pressure (BP) and heart rate (HR)] by physical
training is not well studied.
The heart is continuously exposed to both reactive oxy-
gen and nitrogen species. These species are involved in the
regulation of BP and HR [22,43]. In the heart, three
isozymes of NOS such as endothelial (eNOS), inducible
(iNOS) and neuronal (nNOS) can produce NO under differ-
ent physiological conditions [22]. Although normal endo-
thelial release of NO through eNOS reaction mediates
physiologic vasodilation, excessive release through iNOS
induction may play a role in regulating BP, HR and
endogenous antioxidants in septic shock. The symptoms
of septic shock are relieved in animals and humans by NOS
inhibitors [32]. Acute or chronic administration of NOS
inhibitors has been shown to cause BP elevation and
changes in HR in normal rats [13,46]. Similarly, acute or
chronic physical activity causes alterations in BP and HR
[19,30,42]. However, the mechanisms and molecular alter-
ations in the heart associated with chronic NO-deficient
hypertension and changes in HR during chronic physical
activity are not completely understood. It is hypothesized
that chronic NO-deficient hypertension and alteration in HR
is associated with depletion of antioxidants and oxidative
injury to the heart and exercise training (ET) normalizes the
BP and HR by scavenging free radicals/ROS through up-
regulation of cardiac NO and antioxidant systems. There-
fore, this study investigated the interaction of ET and
chronic NOS inhibitor (nitro-L-arginine methyl ester, L-
NAME) administration on BP and HR and alteration in
NO level, NOS activity and protein expression, antioxidant
enzyme activity and protein expression, GSH levels, protein
oxidation and lipid peroxidation in the heart of rats.
2. Materials and methods
2.1. Chemicals
Chemicals such as GSH, oxidized glutathione (GSSG),
NADPH, g-glutamyl glutamate; enzymes [SOD, CAT,
GSH-Px, GR, glutathione-S-transferase (GST)], 1-chloro-
2,4-dinitrobenzene (CDNB), 1,1,1,1-tetraethoxy-propane,
and L-NAME were purchased from Sigma Chemical Co.
(St. Louis, MO). Coomassie protein assay reagent was
purchased from Pierce Company (Rockford, IL).
2.2. Animals
Male Fisher 344 rats (8–9 weeks of age and 220–240 g
of body weight) from (Harlan Industries, Indianapolis, IN)
were used in this study. The rats were fed ad libitum with
Rodent Laboratory Chow (Ralston Purina Company, Indian-
apolis, IN). Feed consisted of protein (23.4%), fat (4.5%)
and balanced with carbohydrates, fibers, vitamins and
minerals. The rats were maintained on a 12:12 h light/dark
photoperiod. They were randomly divided into four groups
and treated as follows.
Group I [sedentary control (SC)]: Rats were administered
normal saline vehicle [1 ml/kg, subcutaneously (s.c.)] daily
for 8 weeks and were put on the treadmill (Omnitech
Instruments, Columbus, OH) belt for 5 min for equivalent
handling (n = 10).
Group II [ET]: Rats were given ET on treadmill daily for
8 weeks as per published protocol [17,18,41] shown in
Table 1 and were given normal saline 1 ml/kg, s.c. (n = 8).
Group III: [L-NAME]: Rats were administered L-NAME
(10 mg/kg, s.c.) daily in the morning for 8 weeks and put on
treadmill belt daily for 5 min (n = 8).
Group IV: [L-NAME+ET]: Rats were administered L-
NAME (10 mg/kg, s.c.) daily in the morning for 8 weeks
and given ET on treadmill for 8 weeks (n = 6).
The dose of the drug and duration of treatment in rats has
been adapted as per the previous reports [17,20]. The
animals were monitored for body weight changes, exercise
parameters such as oxygen consumption, and respiratory
exchange ratio (RER) throughout the study using compu-
terized Oxyscan system (Omnitech Instruments). The BP
and HR was monitored every week using tail-cuff method
with manometer–tachometer model #KN-201-1 (Natume
Instruments, Japan). The animals were sacrificed by decap-
itation 24 h after the last treatments. The hearts were care-
fully isolated and immediately immersed in liquid nitrogen
and stored at  80 jC until analysis could be completed.
2.3. Determination of GSH and its disulfide (GSSG)
The concentrations of GSH and GSSG were determined
in the tissue by a modified high performance liquid chro-
matography (HPLC) method of Fariss and Reed [10]. The
sensitivity of the HPLC for GSH was 50 pmol/injection
volume and 25 pmol/injection volume for GSSG.
Table 1







1 8 10 30
2 12 10 30
3 16 10 45
4 20 10 45
5 20 10 60
6 20 10 60
7 20 10 60
8 20 10 60
Rats were exercised on treadmill at a belt speed of 8 m/min at 10j angle of
inclination for 30 min during the 1st week, at 12 m/min and same angle of
inclination for 30 min during the 2nd week, at 16 m/min and same angle of
inclination for 45 min during the 3rd week and at 20 m/min and same angle
of inclination for 45 min during the 4th week. During 5th to 8th week, rats
were exercised at a belt speed of 20 m/min and same angle of inclination for
60 min daily.
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2.4. Enzyme assays
SOD activity was determined at room temperature ac-
cording to the method of Misra and Fridovich [28]. SOD
activity was expressed as the amount of enzyme that in-
hibits the oxidation of epinephrine by 50%, which is equal
to 1 unit. Manganese (Mn)-SOD activity was determined
by adding 100 Al of 20 mM NaCN to inhibit copper/
zinc (CuZn)-SOD activity. CuZn-SOD activity was deter-
mined by subtracting the Mn-SOD from the total SOD
activity.
CAT activity was determined at room temperature by a
slight modification of a method of Aebi [1]. The molar
extinction coefficient of 43.6 mM cm  1 was used to
determine CAT activity. One unit of CAT activity was
defined as mmol H2O2 degraded/min/mg protein.
GSH-Px activity was determined by a method of Flohe
and Gunzler [11] at 37 jC. The millimolar extinction
coefficient of 6.22 mM cm  1 was used to determine the
activity of GSH-Px. One unit of activity was equal to Amol
NADPH oxidized/min/mg protein.
GR activity was determined by the method of Carlberg
and Mannervick [3] at 37 jC. The millimolar extinction
coefficient of 6.22 cm  1 was used to determine the activity
of GR. One unit of GR activity was equal to Amol NADPH
oxidized/min/mg protein.
GST activity was assayed by the method of Habig et al.
[15] using 10 mMCDNB as a substrate. The enzyme activity
was calculated using extinction coefficient 9.6 mM cm  1
and expressed as Amol CDNB utilized/min/mg protein.
2.5. Xanthine oxidase (XO) assay
XO activity was assayed as per the modified method
of Singh et al. [39] using 2,2-azino-di (3-ethylbenzthiazo-
line-6-sulfonate (ABST) as chromogen. The enzyme activ-
ity was expressed as Amol hypoxanthine oxidized/min/mg
protein.
2.6. NOS assay
NOS activity was assayed using commercial kit Bioxy-
tech #22113 (Oxis International, Inc., Portland, OR).
2.7. Antioxidant enzyme protein levels by enzyme-linked
immunosorbent assay (ELISA)
The antioxidant enzyme (CuZn-SOD, Mn-SOD, CAT,
GSH-Px and GST) protein levels were determined using the
ELISA technique [17,18].
2.8. Endothelial (eNOS), neuronal (nNOS) and inducible
(iNOS) protein expression assay
The enzyme protein contents of eNOS, nNOS and iNOS
were analyzed using the ELISA technique [17]. Tissue
extracts (0.05 ml) prepared in phosphate-buffered saline
(PBS) (10 mM phosphate buffer, pH 7.4, 150 mM NaCl
and 0.1% sodium azide) were pipetted into each well of
polyvinyl microtiter plate and incubated overnight at 4 jC.
Coating solution was removed and washed three times with
washing buffer (10 mM phosphate buffer, pH 7.4, 150 mM
NaCl, 0.05% Tween 20) and distilled water. Fifty microliters
of monoclonal antibody (eNOS, R&D Systems, Inc., Min-
neapolis, MN; nNOS and iNOS, Upstate Biotechnology,
Lake Placid, NY) diluted in PBS (1:300) were added to each
well, incubated at room temperature for 2 h and washed
three times as before. Fifty microliters of peroxidase-con-
jugated secondary antibody (Sigma) diluted in PBS (1:100)
was added to each well, incubated for 2 h and washed three
times as before. One hundred microliters of substrate (1%
H2O2 and 1 mg/ml 5-amino salicylic acid) in reaction buffer
(0.02 M phosphate buffer, pH 6.8) was added to each well
and incubated for 30 min. The reaction was stopped by
adding 0.1 ml of 3 N NaOH and absorption of the microtiter
wells read at 450 nm using an ELISA reader (Universal
Microplate Reader, Model ExL800, Bio-Tek Instruments,
Inc., Winooski, VT).
2.9. Lipid peroxidation assay
The end product of lipid peroxidation [malondialdehyde
(MDA)] was estimated by the method of Ohkawa et al. [29]
using 1,1,3,3-tetra-ethoxypropane as standard. MDA con-
centration was expressed as nmol/mg protein.
2.10. Protein oxidation
Protein carbonyl content was determined by the modified
ELISA method of Buss et al. [2].
2.11. Nitric oxide assay
NO level in the tissue was determined as (nitrite/nitrate)
by NO assay kit method (Cayman Chemical Company, Ann
Arbor, MI).
2.12. Protein assay
Protein concentration in the tissue was estimated accord-
ing to the method of Read and Northcole [35] using
Coomassie protein assay dye and bovine serum albumin
as a standard.
2.13. Statistical analysis
The data were expressed as meanF S.E. The data for
biochemical and physiological parameters were analyzed
statistically using two-way analysis of variance (ANOVA)
followed by Duncan’s multiple range test using the SAS
statistical software package (SAS Institute, Cary, NC) for
comparison of treated groups with control group. The 0.05
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level of probability was used as the criterion for statistical
significance.
3. Results
The RER significantly (P < 0.001) increased from 1st
week (0.61F 0.03) to 8th week (0.99F 0.04) during ET.
However, no significant change in RER was observed in L-
NAME or L-NAME+ET group up to 8th week. Chronic L-
NAME administration significantly (P < 0.001) increased
BP from 1st week (135F 2.55 mm of Hg) to 8th week
(180F 3.45 mm of Hg). The combination of both L-NAME
and training resulted in normalization of BP close to the
control level (125F 2.25 mm of Hg) in the 8th week.
Chronic L-NAME administration significantly (P < 0.001)
increased HR from 1st week (240F 8 beats/min) to 8th
week (300F 10 beats/min). The combination of both L-
NAME and training resulted in normalization of HR close to
control level (260F 10 beats/min) in the 8th week as
compared to group III (P < 0.001).
The effects of training, chronic L-NAME administration
and the combination of both on cardiac NOS activity, eNOS,
iNOS and nNOS enzyme protein expression and MDA
levels are depicted in Fig. 1. Training for 8 weeks signifi-
cantly elevated cardiac NOS activity (114% of control,
P < 0.05), iNOS protein expression (150% of control,
P < 0.001) and depleted MDA levels (61% of control,
Fig. 1. Effect of ET, chronic NOS inhibitor (L-NAME) treatment and combination of both for 8 weeks on cardiac NOS activity, endothelial NOS (eNOS),
neuronal NOS (nNOS) and inducible NOS (iNOS) protein expressions and MDA levels in rats. Rats were exercised on treadmill and treated with L-NAME at a
dose of 10 mg/kg, s.c., daily for 8 weeks. Each value of the bar graph is expressed as meanF S.E. NOS activity is expressed as nmol NO formed/min/mg
protein; eNOS, nNOS and iNOS enzyme proteins are expressed as Ag/mg protein; MDA level is expressed as nmol/mg protein. * Significant ( P< 0.05) as
compared to sedentary control; ** Significant ( P < 0.001) as compared to sedentary control. + Significant ( P< 0.05) as compared to L-NAME group;
++ Significant ( P< 0.001) as compared to L-NAME group.
Table 2
Effect of ET, chronic NOS inhibitor (L-NAME) treatment and combination of both for 8 weeks on cardiac reduced GSH, GSSG, GSH/GSSG ratio, NO, protein
carbonyl and XO activity in rats
Groups GSH GSSG GSH/GSSG NO Carbonyl XO
(1) SC, n= 10 15.24F 0.61 3.13F 0.24 4.86F 0.30 214.8F 5.0 15.67F 0.19 32.06F 1.02
(2) ET, n= 8 17.98F 1.06 * 2.53F 0.27 7.10F 0.50 ** 238.9F 6.4 ** 15.41F 0.14 30.62F 1.66
(3) L-NAME, n= 8 11.93F 0.83 ** 4.22F 0.32 * 2.82F 0.20 ** 190.6F 4.4 ** 19.94F 0.70 ** 39.62F 1.42 **
(4) Training + L-NAME, n= 6 15.54F 1.10 ++ 2.46F 0.19 * , ++ 6.31F 0.40 * , ++ 220.9F 8.5 ++ 15.65F 0.30 ++ 29.33F 1.97 ++
Rats were exercised on treadmill and given L-NAME at a dose of 10 mg/kg, s.c., daily for 8 weeks.
All the values are expressed as meanF S.E.
GSH, GSSG, NO and protein carbonyl concentrations are expressed as nmol/mg protein and XO activity was expressed as Amol hypoxanthine oxidized/min/
mg protein.
* Significant ( P < 0.05) as compared to group 1.
** Significant ( P < 0.001) as compared to group 1.
++ Significant ( P< 0.001) as compared to group 3.
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P < 0.001). Chronic L-NAME administration for 8 weeks
resulted in a significant depletion of cardiac NOS activity
(55% of control, P < 0.001), eNOS protein (69% of control,
P < 0.001), nNOS protein (69% of control, P < 0.05), iNOS
protein (74% of control, P < 0.001) and MDA levels (128%
of control, P < 0.001). The combination of L-NAME and
training resulted in normalization of cardiac NOS activity,
iNOS, nNOS and eNOS protein expression and MDA
levels, indicating beneficial role of exercise conditioning
on cardiac NO levels.
The effects of training, chronic L-NAME administration
and the combination of both on cardiac GSH, GSSG, GSH/
GSSG ratio, NO levels, protein oxidation and XO activity
are depicted in Table 2. Training significantly increased
cardiac GSH levels (118% of control, P < 0.05), GSH/GSSG
ratio (146% of control, P < 0.001) and NO levels (111% of
control, P < 0.001). Chronic L-NAME administration for 8
weeks significantly depleted cardiac GSH levels (78% of
control, P < 0.001), GSH/GSSG ratio (58% of control,
P < 0.001) and NO levels (89% of control, P < 0.001),
whereas it significantly elevated cardiac carbonyl content
(127% of control, P < 0.001), GSSG levels (135% of con-
trol, P < 0.05) and XO activity (124% of control, P < 0.001).
The combination of L-NAME and training resulted in a
significant increase in cardiac GSH/GSSG ratio (130% of
control, P < 0.05) and depletion of GSSG (79% of control,
P < 0.05), as well as normalization of GSH, NO, protein
carbonyls and XO activity, indicating the beneficial role of
exercise conditioning against L-NAME-induced oxidative
injury to the heart.
The effects of training, chronic L-NAME administration
and the combination of both on cardiac antioxidant enzyme
activities and protein expressions are depicted in Tables 3
and 4. Training for 8 weeks significantly enhanced cardiac
Mn-SOD activity (137% of control, P < 0.05) and protein
expression (115% of control, P < 0.05), CuZn-SOD activity
(115% of control, P < 0.05) and protein expression (124% of
control, P < 0.001), CAT activity (132% of control, P < 0.05)
and protein expression (235% of control, P < 0.05), GSH-Px
activity (112% of control, P < 0.05) and protein expression
(145% of control, P < 0.05) and GR activity (111% of
control, P < 0.05). Chronic L-NAME administration for 8
weeks significantly decreased cardiac Mn-SOD activity
(78% of control, P < 0.05) and protein expression (87%
of control, P < 0.001), CuZn-SOD activity (71% of con-
trol, P < 0.05) and protein expression (71% of control,
P < 0.001), CAT activity (56% of control, P < 0.001) and
protein expression (82% of control, P < 0.001), GSH-Px
activity (88% of control, P < 0.05) and protein expression
(77% of control, P < 0.05), GR activity (82% of control,
Table 3
Effect of ET, chronic NOS inhibitor (L-NAME) treatment and combination of both for 8 weeks on cardiac antioxidant enzyme activities in rats
Groups CuZn-SOD Mn-SOD CAT GSH-Px GR GST
(1) SC, n= 10 45.20F 2.36 30.30F 1.93 14.20F 1.10 190.00F 7.80 52.10F 2.75 6.44F 0.19
(2) ET, n= 8 52.88F 2.05 * 41.62F 4.68 * 18.70F 1.60 * 212.87F 6.80 * 57.75F 1.99 * 6.91F 0.16
(3) L-NAME, n= 8 32.12F 4.21 * 23.62F 2.09 * 8.00F 0.90 * 167.37F 8.02 * 42.75F 1.92 ** 4.71F 0.34 **
(4) Training + L-NAME, n= 6 46.33F 3.69 + 36.00F 3.33 ++ 13.20F 1.40 ++ 219.83F 13.96 * , ++ 50.50F 1.94 + 5.79F 0.04 +
Rats were exercised on treadmill and given L-NAME at a dose of 10 mg/kg, s.c., daily for 8 weeks.
All the values are expressed as meanF S.E.
CuZn-SOD and Mn-SOD activities are expressed as units/mg protein; CAT activity is expressed as mmol H2O2 degraded/min/mg protein; GSH-Px and GR
activities are expressed as Amol NADPH oxidized/min/mg protein; GST activity is expressed as Amol CBNB utilized/min/mg protein.
* Significant ( P < 0.05) as compared to group 1.
** Significant ( P < 0.001) as compared to group 1.
+ Significant ( P < 0.05) as compared to group 3.
++ Significant ( P < 0.001) as compared to group 3.
Table 4
Effect of ET, chronic NOS inhibitor (L-NAME) treatment and combination of both for 8 weeks on cardiac antioxidant enzyme protein levels in rats
Groups CuZn-SOD Mn-SOD CAT GSH-Px GST
(1) SC, n= 10 6.18F 0.60 2.50F 0.14 0.91F 0.04 3.48F 0.37 2.14F 0.15
(2) ET, n= 8 7.67F 0.91 ** 2.88F 0.10 * 2.14F 0.50 * 5.06F 0.51 * 2.45F 0.16
(3) L-NAME, n= 8 4.39F 0.51 ** 2.17F 0.06 ** 0.75F 0.04 ** 2.68F 0.11 * 1.87F 0.13
(4) Training + L-NAME, n= 6 6.70F 0.70 ++ 2.36F 0.05 0.88F 0.05 + 3.85F 0.39 + 2.34F 0.36
Rats were exercised on treadmill and given L-NAME at a dose of 10 mg/kg, s.c., daily for 8 weeks.
All the values are expressed as meanF S.E.
CuZn-SOD, Mn-SOD, CAT, GSH-Px and GST enzyme protein levels are expressed as Ag/mg protein.
* Significant ( P < 0.05) as compared to group 1.
** Significant ( P < 0.001) as compared to group 1.
+ Significant ( P < 0.05) as compared to group 3.
++ Significant ( P < 0.001) as compared to group 3.
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P < 0.001) and GST activity (73% of control, P < 0.001).
The combination of L-NAME and training resulted in a
significant increase of cardiac GSH-Px activity (116% of
control, P < 0.05) and normalization of antioxidant enzyme
activities as well as protein expressions. Interestingly, alter-
ations in antioxidant enzyme activities were well correlated
with enzyme protein expressions in the heart, indicating in-
fluence of exercise and L-NAME on gene regulation of the
enzymes.
4. Discussion
The data show that ET on treadmill for 8 weeks signifi-
cantly increased RER in rats, indicating the conditioning
and adaptation of respiratory system. Previous studies have
also demonstrated a significant increase in RER using ET on
treadmill [18,40]. Anti-hypertensive response and cardiac
adaptation of exercise conditioning has been reported pre-
viously in animals and humans [5,24,42]. The data of the
present study further show that ET significantly increased
cardiac NO levels in rats. Previous studies have also
demonstrated an enhanced release of endothelium-derived
relaxing factor (e.g. NO) in the cardiovascular system of rats
[4,5]. The enhanced cardiac NOS activity and iNOS protein
expressions in the present study clearly indicate the activa-
tion/induction of NOS enzyme activity and de novo syn-
thesis of enzyme proteins in exercise conditioning. All three
NOS isoforms such as constitutive (nNOS and eNOS) and
inducible (iNOS) are expressed in the cardiovascular system
[22]. ET has been previously shown to enhance NO gen-
eration and eNOS expression in the cardiovascular system
of animals [38,49]. However, in the present study, a sig-
nificant induction of iNOS was observed in the heart of rats
after ET, indicating the release of cytokines and other
factors, which induce iNOS. The improvement in the
cardiac functions (BP and HR) by training in rats is also
related to increased blood flow and up-regulation of NOS in
the cardiovascular system causing vasodilation of the ves-
sels [4,5,14]. Training has been reported to improve the
endothelial functions in patients with chronic heart failure
and other cardiovascular disorders [16,30]. The enhanced
production of NO through eNOS activation may cause an
increase in vascular endothelial growth factor (VEGF) and
capillary density leading to enhanced blood flow and vaso-
relaxation in exercise conditioning [21]. The results show
that ET significantly increased cardiac GSH levels and
GSH/GSSG ratio and decreased GSSG levels, indicating
the beneficial effects of the training against oxidative
injuries to the heart. Training depleted cardiac MDA levels
(an end product of membrane lipid peroxidation), indicating
the adaptive response of the training against peroxidative
tissue injuries. The depletion of membrane lipid peroxida-
tion in the heart of trained rats may also be due to inhibitory
action of NO on lipid peroxidation reaction [9,50]. The data
further indicate that cardiac antioxidant enzyme activities
such as Mn-SOD, CuZn-SOD, CAT and GSH-Px signifi-
cantly enhanced after training, indicating the oxidative
conditioning of the heart to get rid of excess ROS generated
during exercise. Earlier studies have shown that only certain
cardiac antioxidant enzyme activities were enhanced in
trained animals [33,41,51]. These variations in the cardiac
antioxidant enzyme adaptation to training may be due to
differences in mode, intensity and duration of the training.
Exercise seems to increase the oxygen consumption rate by
10 to 20 folds and may release the endogenous factors such
as cytokines, tumor necrosis factor (TNF), corticosteriod
hormones and adenosine. These factors are known to
regulate the antioxidant enzyme activities [12,26,31,34]. It
has been reported that the endothelial cells are rich in Mn-
SOD [44] and training increases the NOS [38,49] and NO
levels in the cardiovascular system [17]. It is likely that
redox reaction during exercise activates nuclear factor NF-
kB and thereby induces transcription of antioxidant
enzymes in the heart [17,27,37]. The role of NF-kB has
also been reported in the induction of antioxidant enzyme
expression through NO signaling during ischemic precon-
ditioning of the cardiovascular system [36]. This is the first
report to show the up-regulation of antioxidant enzyme
protein expressions in the heart of exercise-trained rats.
Chronic L-NAME administration in rats resulted in a
significant increase in BP and HR. These physiological
changes were accompanied by depletion of cardiac NO
levels, NOS activity, and iNOS, nNOS and eNOS protein
expressions, indicating the inhibition of NO synthesis in the
heart. Low cardiac NO levels have been shown to induce
positive contractile response of the heart and aorta, leading
to increase in HR and BP [19,22]. NO can regulate both
adenylyl cyclase and guanylyl cyclase in the heart and aorta
[48] and regulate the BP and HR. The data further indicate
that chronic administration of L-NAME to rats significantly
elevated the cardiac MDA levels, protein carbonyl contents
and XO activity, indicating enhanced lipid peroxidation,
protein oxidation and superoxide production due to chronic
NOS inhibition. Overproduction of ROS (oxidative stress)
in the cardiovascular system through XO activation creates
both an imbalance in NO signaling and changes in other
intracellular signaling pathways [25] leading to contraction
and hypertension [52]. Interestingly, during the initial phase
of NOS inhibition, inflammatory reactions were reportedly
followed by pathological changes in the cardiovascular
system in the later phase [45]. This report further suggests
the role of free radicals/ROS and oxidative tissue injury in
the course of NOS inhibition. Chronic administration of L-
NAME significantly decreased cardiac GSH/GSSG ratio by
depleting the GSH, and increasing GSSG clearly demon-
strates the oxidative stress response during NOS inhibition.
Depletion of GSH and GSH/GSSG ratio in blood has been
reported to be a good marker in hypertension [17,47].
Interestingly, depletion of tissue GSH by buthionine sul-
foximine (BSO) in rats has been demonstrated to increase
BP [47]. Chronic L-NAME administration significantly
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decreased cardiac antioxidant enzyme activities as well as
protein expressions in rats. The down-regulation of cardiac
antioxidant enzymes may be related to the cell signaling
function of NO to maintain the antioxidant enzyme status in
the heart.
The interaction of training and chronic L-NAME admin-
istration restored the elevation in BP and HR induced by L-
NAME administration alone. Physical training has been
shown to reduce the BP and HR in animals as well as in
humans [24,42]. These effects of the training are related to
increase capillary blood flow, tissue oxygen utilization,
vasodilation and angiogenesis through NO production in
cardiovascular system [8,14,38,49] Thus, reduced cardiac
NO levels, nNOS and iNOS protein expressions, and
elevated MDA, protein carbonyls and XO activity caused
by chronic NOS inhibition in rats as observed in the present
study are normalized by training. Training has been reported
to normalize the cardiac energy metabolism in mammals
with hypertension [23]. The interaction of training and
chronic NOS inhibition also normalized cardiac GSH/GSSG
ratio in rats, which was suppressed in L-NAME alone treated
group. The data further demonstrate that interaction of
training and chronic NOS inhibition attenuated the decrease
in cardiac antioxidant enzyme activities caused by L-NAME
administration. These observations suggest that training up-
regulated the antioxidant defense system. Moreover, cardiac
antioxidant enzyme (CuZn-SOD, Mn-SOD, CAT, GSH-Px,
GR and GST) protein levels were normalized in the combi-
nation group as compared to L-NAME treated group. This is
the first report to show that exercise conditioning not only
activates the antioxidant enzyme activities but also induces
the enzyme protein expression in cellular compartments of
the heart in L-NAME treated rats.
It is concluded that aerobic exercise conditioning pro-
vided significant protection against oxidative injury in L-
NAME treated rats by up-regulating the cardiac antioxidant
defense system, inhibiting protein oxidation, lipid peroxi-
dation and preserving the BP and HR.
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